Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Double-Masked Adaptive Design Evaluation of the Safety and Preliminary Efficacy of IVMED-85 on Pediatric Myopia

Trial Profile

A Randomized, Controlled, Double-Masked Adaptive Design Evaluation of the Safety and Preliminary Efficacy of IVMED-85 on Pediatric Myopia

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IVMED 85 (Primary)
  • Indications Degenerative myopia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors iVeena Delivery Systems

Most Recent Events

  • 29 May 2025 According to an iVeena Delivery Systems media release, company announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IVMED-85 for the treatment of pediatric myopia.
  • 05 Feb 2025 According to an iVeena Delivery Systems media release, all IND-enabling studies are well underway supporting a targeted IND submission in H1-2025
  • 05 Feb 2025 According to an iVeena Delivery Systems media release, the company is expected to begin a Phase 2 clinical study in progressive myopia in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top